560. Deputy Billy Kelleher asked the Minister for Health his views that the price of two of the largest medicines supplied by the Health Service Executive, Humira and Enbrel, at a cost of €160 million per year, will not experience significant price reduction when their patents fall in 2017, as a direct result of the terms of the forthcoming medicine pricing agreement with the Irish Pharmaceutical Healthcare Association, because the terms in this agreement will prevent effective post-patent competition; and if he will make a statement on the matter. [21016/16]

Summary

560. Deputy Billy Kelleher asked the Minister for Health his views that the price of two of the largest medicines supplied by the Health Service Executive, Humira and Enbrel, at a cost of €160 million per year, will not experience significant price reduction when their patents fall in 2017, as a direct result of the terms of the forthcoming medicine pricing agreement with the Irish Pharmaceutical Healthcare Association, because the terms in this agreement will prevent effective post-patent competition; and if he will make a statement on the matter. [21016/16]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Medicinal Products Prices

  xml · EN · 12 July 2016

  ViewDownloadOpen at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.